Zobrazeno 1 - 10
of 93
pro vyhledávání: '"Debu, Tripathy"'
Autor:
Charles L, Vogel, Melody A, Cobleigh, Debu, Tripathy, John C, Gutheil, Lyndsay N, Harris, Louis, Fehrenbacher, Dennis J, Slamon, Maureen, Murphy, William F, Novotny, Michael, Burchmore, Steven, Shak, Stanford J, Stewart, Michael, Press
Publikováno v:
Journal of Clinical Oncology. 41:1638-1645
PURPOSE To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS One hundred fourteen women with HER2-overexpressing metastatic breast cancer were ran
Autor:
Savitri Krishnamurthy, Parag Jain, Debu Tripathy, Roland Basset, Ramandeep Randhawa, Hassan Muhammad, Wei Huang, Hua Yang, Shivaani Kummar, George Wilding, Rajat Roy
Publikováno v:
JCO Clinical Cancer Informatics.
PURPOSE Achieving a pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) is associated with improved patient outcomes in triple-negative breast cancer (TNBC). Currently, there are no validated predictive biomarkers for the response
Publikováno v:
JCO Oncol Pract
The clinical progression patterns of metastatic breast cancer (MBC) are heterogeneous; patients experience acute and stable phases at different time points. The acute phase consists of rapid progressive symptomatic changes, whereas in the stable phas
Autor:
Blessie Elizabeth Nelson, Sadia Saleem, Senthil Damodaran, Neeta Somaiah, Sarina Anne Piha-Paul, Julia Ann Moore, Bulent Yilmaz, Daniel D. Karp, Ecaterina Elena Dumbrava, Apostolia Maria Tsimberidou, David S. Hong, Jordi Rodon Ahnert, Daniel J. Booser, Nuhad K. Ibrahim, Anthony Paul Conley, Priya Bhosale, Cristhiam Mauricio Rojas Hernandez, Debu Tripathy, Aung Naing, Funda Meric-Bernstam
Publikováno v:
Journal of Clinical Oncology. 40:3108-3108
3108 Background: Selinexor (KPT-330) is potent inhibitor of Exportin-1. In vitro, Selinexor was found to be synergistic with eribulin in triple negative breast cancer (TNBC) cell lines and enhanced antitumor activity of eribulin in TNBC patient-deriv
Autor:
Janice M. Lu, Kevin Kalinsky, Debu Tripathy, George W. Sledge, William John Gradishar, Ruth O'Regan, Joyce O'Shaughnessy, Shanu Modi, Haeseong Park, Amelia McCartney, Sophia Frentzas, Catherine M. Shannon, Richard Wilhelm Eek, Miguel Martin, Giuseppe Curigliano, Guy Heinrich Maria Jerusalem, Chiun-Sheng Huang, Michael F. Press, Sara M. Tolaney, Sara A. Hurvitz
Publikováno v:
Journal of Clinical Oncology. 40:TPS1112-TPS1112
TPS1112 Background: The overexpression and/or amplification of human epidermal growth factor receptor 2 (HER2) occurs in approximately 20% of breast cancers (BC) and is a major driver of tumor development and progression. This HER2 subtype confers ag
Autor:
Jason A Mouabbi, Akshara Singareeka Raghavendra, Roland L. Bassett, Amy Aida Hassan, Debu Tripathy, Rachel M. Layman
Publikováno v:
Journal of Clinical Oncology. 40:1067-1067
1067 Background: The majority of invasive lobular breast cancers (ILC) are hormone receptor (HR)-positive, HER2-negative and are clinically treated similarly to HR+ HER2-negative invasive ductal cancers (IDC). However, ILC differs distinctly from IDC
Autor:
Kenna R. Mills Shaw, Debu Tripathy, Senthil Damodaran, Funda Meric-Bernstam, Mehmet Esat Demirhan, Aysegul A. Sahin, Filip Janku, Xiaofeng Zheng, Agda Karina Eterovic, Lauren Brusco, Tae-Beom Kim, Ken Chen, Maryam Shariati, John Mendelsohn, Reva K. Basho, Gordon B. Mills, Jordi Rodon, Naoto T. Ueno, Russell Broaddus, Chetna Wathoo, Coya Tapia
Publikováno v:
JCO Precision Oncology. :1-15
Purpose To determine the significant genomic alterations in patients with metastatic breast cancer (MBC) and survival outcomes in common genotypes. Patients and Methods High-depth next-generation sequencing was performed for 202 genes in tumor and no
Autor:
Debu Tripathy, Senthil Damodaran, Akshara Singareeka Raghavendra, David Ramirez, Nicole M. Kettner, Yu Shen, Kelly K. Hunt, Dan S. Gombos, Khandan Keyomarsi, Danielle N. Kwiatkowski
Publikováno v:
Journal of Clinical Oncology. 39:1067-1067
1067 Background: Endocrine therapy with a CDK4/6 inhibitor is standard of care for patients (pts) with estrogen-receptor-positive (ER+), HER2-negative MBC, yet resistance ultimately develops. We have shown that low doses of palbociclib activates auto
Autor:
Debu Tripathy, Yao Wang, Lara Zuberi, Joseph C. Cappelleri, Aldemar Montero, Joanne L. Blum, Kenneth Manning, Marc Drucker, Meghan Sri Karuturi, Gabrielle B. Rocque, Christopher Gallagher, Lloyd A. Shabazz
Publikováno v:
Journal of Clinical Oncology. 39:1071-1071
1071 Background: Racial disparities in breast cancer incidence, mortality, and care are well documented. PAL plus endocrine therapy is indicated for patients (pts) with HR+/HER2− ABC. Findings from the PALOMA clinical trials have shown that pts rec
Autor:
Debu Tripathy, Rashmi Krishna Murthy, Aki Morikawa, Ariel Topletz-Erickson, Antonio C. Wolff, Ian E. Krop, Erica Stringer-Reasor, Jason B White, Kim LaMaster, Michelle E. Melisko, Jennifer L. Childress, Barbara O’Brien, Kristen O. Riley, John de Groot, Vicente Valero, Mina Lobbous, Nan Lin, Mothaffar F. Rimawi
Publikováno v:
Journal of Clinical Oncology. 39:1044-1044
1044 Background: Tucatinib is a potent and highly selective HER2-targeted tyrosine kinase inhibitor approved for use in combination with trastuzumab and capecitabine for patients with metastatic HER2+ breast cancer (MBC) who have received ≥1 prior